Measurement of C1-Inhibitor function alone is sufficient for diagnosis of hereditary angioedema

Hereditary angioedema (HAE) types 1 and 2 are rare autosomal dominant disorders due to reduced levels or dysfunctional C1-Inhibitor (C1-INH). This results in dysregulation of the contact kinin system and over production of bradykinin, which causes extravasation of fluid and recurrent debilitating and life-threatening subcutaneous and submucosal swellings. The WAO/EAACI (2018) consensus guidelines on HAE state that “all patients suspected to have HAE-1/2 [should be] assessed for blood levels of C1-INH function, C1-INH protein, and Complement (C4). If the levels of any of these analytes are abnormally low, the tests should be repeated to confirm the diagnosis of HAE-1/2.” The guidelines do not comment on other testing paradigms and in practice C4 with or without C1-Inhibitor levels are tested in most immunology laboratories. A low C4 can be observed during an attack but in many patients it remains low in between attacks and hence, it can be used for screening but it could miss a number of patients. C1-INH levels can be normal in patients with HAE type 2. C1-INH function is low in both HAE 1 and 2 patients. C1-INH levels could/can be accurately measured by radial immunodiffusion (RID). It uses small amounts of serum and has high analytic sensitivity but apart from not being suitable for HAE type 2, it is time consuming. It needs set up time and reading time 72 hours later. The newer methods are mostly used on automated analysers that require larger serum volume and so problematic in testing small children. The cost of C1-INH antigenic level and function are very similar, but C4 is much cheaper than both.

We analysed the requests to our laboratory for C1-INH level and function over a 6 months period to April 2019. A total of 441 requests were sent to the lab, 368 of which were normal. Of the 73 abnormal results that could be diagnosed with HAE, all (100%) had abnormal C1-INH function but 8 (10.9%) had normal C1-INH levels thus potentially missing a diagnosis of HAE if antigenic level only were tested. Therefore the sensitivity of C1-INH function was 100% compared to 89.1% for C1-INH levels.

The paradigm for testing in our laboratory has changed to initial measurement of C1-INH function followed by measuring C1-INH and C4 levels only if the function is abnormal. This change has resulted in a faster turn-around time and significant savings. Considering that HAE is a rare disease (approx. 1:25000) and majority of patients investigated do not have this condition, our data shows that this change of strategy reduces costs significantly without affecting the clinical sensitivity.

References
1. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. World Allergy Organization Journal 2018:1(1)